CAl25与慢性肝病相关性研究进展  

CA125 and chronic liver diseases ：an update

作　　者：唐平 张珊珊 

机构地区：[1]肥城市人民医院,山东肥城271600

出　　处：《医药前沿》2017年第14期5-7,共3页Journal of Frontiers of Medicine

摘　　要：肿瘤标志物常用于筛查、诊断和鉴别恶性疾病，癌抗原CA125被认为是妇科肿瘤最重要和可靠的血清学诊断指标。但近年来研究表明，CA125除在卵巢癌等恶性肿瘤升高外，许多良性疾病也有明显升高，特别是在慢性肝病中的报道较多。研究表明，CA125在肝硬化患者中明显升高，并随肝硬化程度加重而进行性增加，病因考虑与腹水一血清交换、肝脏代谢降低及雌激素灭活障碍等机制有关。因此，有学者认为CA125可以作为反应肝硬化程度及监测腹水情况的一项敏感指标，对肝硬化腹水早期诊断及估计预后具有重要的指导意义。本文综述了近年来关于CA125与慢性肝病相关性的研究进展。Trumor biomarkers areused for screening, diagnosis and stratification of malignant diseases, cancer antigens 125（CA125） was considered the most important and reliable gynecological tumor serological diagnosis index. But in recent years studies have shown that, CA125 in malignancies such as ovarian cancer increased, many diseases also have increased, especially in the reports of chronic liver diseases.Studies have shown that, CA125 was significantly higher in patients with liver cirrhosis, progressive increase along with the aggravating the degree of liver cirrhosis due to ascites - serum exchange, reduce liver metabolism disorders and estrogen inactivation mechanisms. Therefore, some scholars believe that CA125 in liver cirrhosis patients have a osculating correlation with lesion of the liver and astites degree, may serve as a sensitive marker for liver lesion degree and monitoring astites quantity, and are of value to early diagnosis and estimating prognosis for liver cirrhosis patients with astites. This article reviewed research progress and clinical use of the tumor marker CA125 in patients withchronic liver diseases.

关 键 词：慢性肝病 肿瘤标志物 癌抗原125 腹水 

分 类 号：R446.6[医药卫生—诊断学]